Censavudine, formerly known as OBP-601, BMS-986001 or festinavir, is a nucleoside reverse transcriptase inhibitor that is active against HIV resistant to both abacavir and tenofovir, making the drug a candidate for people with multi-drug resistant (MDR) strains of the virus. Censavudine is a analogue of stavudine (d4T), but is less toxic. Censavudine has demonstrated potent in vitro activity against HIV-2, including HIV-2 mutants containing the K65R and Q151M reverse transcriptase substitutions. References: Gupta SK, McComsey GA, Lombaard J, Echevarría J, Orrell C, Avihingsanon A, Osiyemi O, Santoscoy M, Ray N, Stock DA, Joshi SR, Hanna GJ, Lataillade M. Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial. Lancet HIV. 2016 Jan;3(1):e13-22. doi: 10.1016/S2352-3018(15)00231-3. Epub 2015 Dec 12. PubMed PMID: 26762988.

纯度：≥98%

CAS：634907-30-5